University of Manitoba
Is Empagliflozin equivalent and/or synergistic with ACE inhibition in the treatment of chemotherapy mediated cardiotoxicity?
Abstract
dc:description.abstractBackground: Doxorubicin and Trastuzumab (DOX+TRZ) are two of the most commonly used anti-cancer medications for treating breast cancer. Although these two drugs enhance overall survival rates in women with breast cancer, they are associated with an increased risk of cardiotoxicity. Various randomized controlled trials have demonstrated that sodium-glucose co-transporter 2 (SGLT2) inhibitors, such as Empagliflozin (EMPA), reduce the risk of hospitalizations and mortality due to heart failure in patients with and without diabetes. However, little is known about the potential effects of SGLT2 inhibitors in treating DOX+TRZ mediated cardiotoxicity. Objective: The objective of this thesis is to assess whether the effectiveness of the SGLT2 inhibitor EMPA treatment is similar to and/or synergistic with the standard drug therapy using the RAS inhibitor perindopril (PER) in treating DOX+TRZ-induced cardiomyopathy. Methods: For the 6-week study, a total of 130 C57Bl/6 female mice were randomly assigned to receive weekly treatment with saline (n = 30) or DOX+TRZ (n = 100) intraperitoneally for 3 weeks to establish a chronic in vivo murine model of chemotherapy induced cardiotoxicity. Mice were treated with PER (3 mg/kg), EMPA (10 mg/kg) or EMPA+PER by oral gavage for an additional 3 weeks for a total of 6 weeks. Echocardiography was performed on a weekly basis and at the end of week 6, the mice were euthanized for histological and biochemical analyses. Results: In mice treated with DOX+TRZ (n=15), the left ventricular ejection fraction (LVEF) decreased from 74±4% at baseline to 37±6% at week 6. Mice treated with either PER, EMPA, or EMPA+PER via oral gavage demonstrated an improvement in LVEF of 62±4%, 63±3%, and 64±4%, respectively (p<0.05) (Figure 1). Histological analyses confirmed significant disruption of myofibrils, vacuolization, and loss of sarcomere integrity in the DOX+TRZ treated mice. Oral gavage with EMPA and EMPA+PER, however, improved myofibril integrity at week 6 in mice receiving DOX+TRZ. Finally, the Bax/Bcl-xL ratio, a marker of apoptotic signalling, was significantly increased by approximately 2-fold in mice receiving DOX+TRZ on Western analyses. This increase was attenuated by treatment with PER, EMPA, or the combination of EMPA+PER. Conclusion: EMPA was equivalent to PER in the treatment of DOX+TRZ mediated cardiotoxicity.
Degree
thesis:*- Level thesis:degree_level
- Master of Science (M.Sc.)
- Discipline thesis:degree_discipline
- Physiology and Pathophysiology
- Year dc:date.issued
- 2026
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Ali, Sumha
- Advisor dc:contributor.supervisor
-
- Jassal, Davinder
- Committee members dc:contributor.committeemember
-
- Ravandi, Amir (Internal Medicine)
- Dhingra, Sanjiv (Physiology and Pathophysiology)
- Wigle, Jeffrey (Biochemistry and Medical Genetics)
Subjects
dc:subject × 10Rights
- Language dc:language.iso
- eng
Identifiers
dc:identifier.*- Handle dc:identifier.uri
- http://hdl.handle.net/1993/39733